“The Buzz” Show: Outlook Therapeutics, Inc. (NASDAQ: OTLK) Trial for Wet AMD Treatment | Financial Buzz

“The Buzz” Show: Outlook Therapeutics, Inc. (NASDAQ: OTLK) Trial for Wet AMD Treatment

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Outlook Therapeutics, Inc. Surges Upon Announcing Positive Results from Trial for Wet AMD Treatment

Outlook Therapeutics, Inc. (NASDAQ: OTLK) surged over 33% in premarket trading after the company announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy.

The NORSE TWO pivotal Phase 3 clinical trial enrolled a total of 228 subjects with wet AMD across 39 clinical trial sites in the United States, with ONS-5010 deemed safe and well tolerated after it achieved statistically significant and clinically relevant primary and key secondary efficacy endpoints.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO.

For more information, please visit: Outlook Therapeutics, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!